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ABSTRACT
Objectives: Assess the relationship between migraine fre-
quency and health utility.
Methods: Patients aged 18 years diagnosed with episodic
migraine were enrolled at three US sites representing varied
models of health-care delivery. All subjects completed a ques-
tionnaire that included demographic and clinical informa-
tion, a migraine-speciﬁc disability questionnaire, and the
Health Utilities Index Mark 3 (HUI3). The HUI3 is a generic
health status and health-related quality-of-life measure.
HUI3 health status data are translated into utility scores
anchored by 0 (dead) and 1 (perfect health).
Results: The study enrolled 150 patients. The mean age was
44 years and 87% were female. Mean (SD) monthly
migraine frequency was 4.4  3.6, with 34% reporting 2
migraines per month and 20% reporting >6 migraines per
month. The mean (SD) HUI3 score was 0.62  0.26. After
controlling for study center, demographics, comorbidities,
migraine characteristics, and level of migraine disruptiveness,
migraine frequency was found to be signiﬁcantly (P < 0.05)
and negatively associated with HUI3 scores. Subjects with >6
migraines per month had an adjusted mean HUI3 score of
0.41; the corresponding mean for those reporting 2
migraines per month was 0.67. Migraine frequency was posi-
tively associated with higher levels of disability for the
emotion, cognition, and pain components of the HUI3.
Conclusions: Among this group of care-seeking patients,
migraineurs’ health utilities were inversely related to head-
ache frequency. Although these data may not be generalizable
to the entire migraine population, they may be useful in
assessing the comparative cost-effectiveness of preventive
migraine therapies.
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Introduction
Migraine is a common neurological disorder charac-
terized by severe, disabling headaches usually accom-
panied by nausea or vomiting, photophobia, and
phonophobia [1]. Approximately 6% of men and 18%
of women in the United States have experienced
migraine, with peak prevalence occurring during prime
working years (aged 25 to 55 years) [2–4]. About 50%
of migraineurs experience an estimated 1.5 attacks per
month, and up to one-quarter experience one or more
attacks weekly [3]. The most recent national epide-
miological survey of migraine found that 23% of
migraineurs had less than one attack per month, and
63% had one to four attacks per month [4]. Despite its
prevalence, and the emergence of effective treatment
options, many migraine sufferers remain undiagnosed
or receive inadequate clinical management [5,6]. Diag-
nosis and management of migraine are complicated by
broad and varied clinical characteristics and frequent
concomitance with other neurological conditions such
as depression, panic disorder, general anxiety, and
epilepsy [7–9].
The economic burden of migraine is substantial
because migraine predominately affects young and
otherwise productive individuals [10,11]. The major-
ity of this economic burden is related to indirect costs
such as absenteeism or reduced/lost workplace pro-
ductivity (i.e., “presenteeism”) borne by employers
[11,12]. Direct health-care costs, including those
related to drug treatment, physician services, diagnos-
tic testing, hospitalization, and emergency room
treatment, are also substantial—potentially exceeding
$1 billion annually [12,13]. Direct health costs for
migraineurs have been estimated to be at least
$50 more per month as compared to a cohort of
nonmigraineurs [14].
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Migraine has considerable negative effects on quality
of life [9,15–18], with some evidence suggesting that the
general well being of migraineurs may be impaired even
between attacks [19]. Persons with migraine have difﬁ-
culty relating to family members [20,21], and regular
activities such as housework and social plans are often
delayed or canceled because of illness [2,3,15,20].
Studies using the Medical Outcomes Study Short
Form-36 (SF-36) (and variations such as the SF-8D and
SF-12) have found that migraine sufferers have lower
health-related quality of life than nonmigraineurs,
with more pain and restriction in their daily activities
than patients with many other chronic conditions
(e.g., depression, osteoarthritis, and diabetes)
[9,15,17,18,22].
Although there is a rich survey-based literature on
migraine incidence, treatment, and disease burden
[3–5], there are limited data on the frequency of
migraine attacks in clinical practice (e.g., average
migraines per month for treatment-seeking patients)
and on the relationship between frequent migraines
and health status, particularly as measured by health
utilities [9]. Health utilities, a type of health preference
measure used to quantify the preferences of individuals
for particular health states, typically vary from 0
(dead) to 1 (perfect health). Distinct from generic
health status measures, health utilities also are useful
for cost-effectiveness analyses and comparing health
state preferences across diseases. Therefore, we set out
to measure health utility among a cohort of migraine
patients and relate migraine frequency to health utility
scores.
Methods
Study Design
A cross-sectional survey was administered to patients
aged 18 years who were physician-diagnosed with
episodic migraine at least 1 year before study enroll-
ment (based on medical chart review at the time of
recruitment), and who were not experiencing a
migraine at the time of recruitment. Patients were
enrolled at three US sites, including a primary care
group practice, a specialty headache clinic, and a non-
proﬁt HMO group practice. The sites were selected
based on their established experience in conducting
clinical research and to provide diversity in geography,
patient population, and treatment setting. The princi-
pal investigator at each study site was responsible
for veriﬁcation of study inclusion criteria, including
migraine diagnosis. A minimum level of monthly
migraine frequency was not an inclusion criterion.
Each site enrolled consecutive patients until their
quota of 50 patients was reached (target enrollment
was 150 patients). The surveys were completed
between April and September 2004. Before study ini-
tiation, a 10-patient pilot study was conducted to
ﬁnalize the survey instrument. Patients provided
written informed consent. Institutional Review Boards
approved the study.
Study Measures
All subjects completed a questionnaire that included
items regarding demographic (i.e., age, sex, income,
education, race/ethnicity, insurance status, and
employment status) and clinical information (monthly
migraine frequency, selected comorbidities [yes/no],
current use of acute and preventive medications, and
overall prescription drug use). To assess comorbidities,
we asked patients if they had ever been told by a
doctor that they had any of the following conditions:
depression, hypertension, arthritis, asthma, epilepsy,
diabetes, congestive heart failure, renal disease, heart
attack, or stroke. Migraine-speciﬁc questions included
age at migraine onset, migraine severity (pain on a
scale of 1–10), presence of aura, duration of typical
migraines (<6 hours, 6–12, 12–24, and >24 hours),
disruptiveness of migraines (ﬁve-item Likert scale
ranging from “not at all” to “somewhat” to “very”
disruptive), and migraine-related disability using the
Migraine Disability Assessment (MIDAS) question-
naire (3-month recall period). The MIDAS is a brief,
widely used questionnaire that captures information
on migraine disability over the previous 3 months in
terms of missed days of paid work (or school), house-
hold work (chores), and nonwork time (family, social,
and leisure activities). MIDAS scores are summed and
grouped into four disability categories, ranging from
“little or none” to “severe” [23].
The primary study outcome—health utilities—was
assessed using the Health Utilities Index Mark 3
(HUI3). The HUI3 is a generic and widely used
patient-reported measure of health status. It is a
15-item questionnaire focusing on eight health status
attributes (vision, hearing, speech, ambulation, dexter-
ity, emotion, cognition, and pain), each with ﬁve or six
levels of disability, for a total of 972,000 different
health states [24,25]. A 4-week recall period was used
for this study. The attributes are weighted according to
preferences obtained from a community sample in
Ontario, Canada, and were based on a visual analog
scale and standard-gamble assessments [24]. The cat-
egorical health status measures are combined into a
single global utility score and single attribute scores
using a multiplicative multi-attribute utility function.
Global and single component scores are interpreted as
health utilities, and are anchored by 0 (dead) and 1
(perfect health). The HUI3 has been extensively vali-
dated in a variety of settings, conditions, and countries
[25–27].
Analyses
Bivariate and multivariate (analysis of covariance)
analyses were undertaken to assess the relationship
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between HUI3 and migraine frequency. The multivari-
ate analyses controlled for study center, demographics
(age, sex, and income), presence of depression, pres-
ence of any other selected comorbidity (e.g., arthritis,
hypertension, asthma), migraine characteristics
(migraine severity, presence of aura, and duration),
and the level of disruptiveness of migraine to family
and friends. We included migraine frequency as a con-
tinuous variable in the main model to test the signiﬁ-
cance of the association between migraine frequency
and HUI3 scores. A separate model speciﬁed migraine
frequency categorically (<2, >2–4, >4–6, >6 migraines
per month) to generate adjusted means for each
migraine frequency category. Alternative statistical
models that included selected interaction terms (e.g.,
migraine frequency by site and age) and different cova-
riate speciﬁcations for migraine pain, duration, and
disruptiveness were constructed to assess the robust-
ness of the model estimates. The level of migraine
disability was assessed descriptively using MIDAS.
All analyses were performed using SAS Version 9.0
statistical software (SAS Institute, Cary, NC). Data
quality procedures were performed on an ongoing
basis throughout the data collection period. One study
subject provided multiple responses to individual items
and therefore was excluded from the HUI3 analysis.
The midpoint was used in cases in which a subject
provided a range instead of a discrete number for
monthly migraine frequency (e.g., 4–5 migraines per
month was recorded as 4.5).
Results
Each site enrolled 50 subjects, achieving our target
enrollment of 150. The mean (SD) age was
44  11.6 years, 87% were female, and 87% reported
their race as white (Table 1). Subjects had an average of
24 years of migraine history, and 41% reported current
use of preventive therapy for migraine. Migraines were
described as “moderately” or “very” disruptive to
friends and family by 45% of subjects. Subjects
reported a mean (SD) monthly migraine frequency of
4.4  3.6, with 34% reporting 2 migraines per
month and 20% reporting >6 per month (Table 2).
MIDAS Grade IV (severe) disability was reported by
16% of subjects with two or fewer migraines per
month, 42% of those with >2–4 migraines per month,
56%of thosewith >4–6migraines permonth, and 69%
of those with more than six migraines per month
(Table 3). Interestingly, one-third of those with two or
fewer migraines per month reported moderate to severe
disability based on MIDAS.
The median (mean  SD) HUI3 global utility score
was 0.66 (0.62  0.26). One in four had HUI3 scores
of less than 0.50, and only one in nine had HUI3 scores
of at least 0.90. HUI3 global utility scores were lowest
in those with frequent migraines and for those who
reported that their migraines were disruptive to family
and friends. The mean (SD) HUI3 global utility score
was 0.68 (0.25) for those reporting2 migraines per
month, and 0.55 (0.22) for those reporting >6
migraines per month. Subjects with self-described
“very disruptive” migraines to others had a mean
HUI3 global utility score of 0.56.
After controlling for study site, demographics,
comorbidities, migraine characteristics, and level of
disruptiveness of migraine to family and friends, as
well as the interaction between age and migraine fre-
quency, migraine frequency (speciﬁed as a continuous
variable) was signiﬁcantly (P < 0.025) and negatively
associated with the HUI3 global utility score. Other
migraine characteristics (pain severity [P < 0.77], pres-
ence of aura [P < 0.07], and duration [P < 0.36]) were
not found to be statistically signiﬁcant predictors of
HUI3 scores (Table 4). Findings from the alternative
Table 1 Characteristics of study subjects
Characteristic
Total
N %
Age (years)
18–34 33 22.0
35–44 41 27.3
45+ 76 50.7
Mean age (SD) 44.4 (11.6)
Sex
Male 20 13.3
Female 130 86.7
Race/ethnicity
White 131 87.3
African American 10 6.7
Hispanic 5 3.3
Other 4 2.7
Education
High school graduate 76 50.7
College graduate 73 48.7
Missing 1 0.7
Annual family income
Under $40,000 51 34.0
$40,000–$59,000 35 23.3
$60,000+ 61 40.7
Missing 3 2.0
Selected comorbidities
Other pain (neck and back pain) 41 27.3
Depression 38 25.3
Arthritis 26 17.3
Asthma 16 10.7
Hypertension 13 8.7
Diabetes 3 2.0
Epilepsy 1 0.7
Employment status
Full-time 90 60.0
Part-time 22 14.7
Homemaker 17 11.3
Not employed 11 7.3
Retired 6 4.0
Other 3 2.0
Missing 1 0.7
Insurance
Private health plan 128 85.3
No insurance (self-pay) 13 8.7
Government health plan 6 4.0
Other 2 1.3
Disability insurance 1 0.7
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models with different covariate speciﬁcations were
consistent with the primary model result that showed
migraine frequency was statistically and negatively
associated with health utility. The adjusted mean HUI3
global utility score was inversely related to migraine
frequency when grouped into four categories, HUI3
global utility score ranged from 0.67 in subjects with
2 migraines per month to 0.41 for those experiencing
more than six migraines per month and this trend was
signiﬁcant (P = 0.043) (Table 5).
Only 2% of subjects reported no disability on any
HUI3 attribute. Nine percent reported disability on
only one HUI3 attribute, and 41% reported disability
on four or more of the HUI3 attributes. The three
HUI3 attributes most impacted by migraine frequency
were emotion, cognition, and pain (Fig. 1). The mean
single attribute utility scores for emotion (0.89) and
cognition (0.88) were signiﬁcantly lower (P < 0.001)
than the mean scores for vision, hearing, speech,
ambulation, and dexterity. The mean HUI3 score for
pain (0.71) was signiﬁcantly lower than all other HUI3
components (P < 0.001).
Table 2 Migraine characteristics of study subjects
Characteristic
Total
N %
Age at onset (years)
Under 18 69 46.0
18–24 29 19.3
25–34 25 16.7
35+ 26 17.3
Missing 1 0.7
Migraine history
Mean years with migraine (SD) 24.0 (12.8)
Migraine type
Migraine with aura 49 32.7
Migraine without aura 101 67.3
Migraine pain (1 =mild, 10 = severe)
1 to 4 5 3.3
5 to 7 64 42.7
8 to 10 76 50.7
Missing 5 3.3
Mean migraine pain level (SD) 7.5 (1.6)
Migraine duration
Less than 6 hours 31 20.7
6 to 12 hours 41 27.3
13 to 24 hours 41 27.3
24+ hours 37 24.7
Disruptiveness of migraines
Not at all 6 4.0
A little 39 26.0
Somewhat 37 24.7
Moderately 51 34.0
Very 17 11.3
Migraine treatments
Reporting acute medication use 144 96.0
Reporting any current preventive
Medication use 62 41.3
Monthly migraine frequency
2 51 34.0
>2 to 4 44 29.3
>4 to 6 25 16.7
>6 30 20.0
Mean frequency (SD) 4.4 (3.6)
Table 3 Migraine Disability Assessment (MIDAS) by patient-reported monthly migraine frequency and mean HUI3 score
Number of patient-reported
migraines per month
Migraine Disability Assessment grade*
I. Little or
no disability
II. Mild
disability
III. Moderate
disability
IV. Severe
disability
N % N % N % N %
2 12 24.5 20 40.8 9 18.4 8 16.3
>2 to 4 5 11.6 5 11.6 15 34.9 18 41.9
>4 to 6 1 4.0 2 8.0 8 32.0 14 56.0
>6 3 10.3 2 6.9 4 13.8 20 69.0
*MIDAS data were missing for 4 subjects.
HUI3, Health Utilities Index Mark 3.
Table 4 Predictors of HUI3 scores according to multivariate
analysis of covariance
Characteristic Parameter estimate P-value
Age (years)
<35 Reference category
35–44 -0.359 <0.001
45+ -0.194 0.026
Sex
Female Reference category
Male 0.041 0.443
Annual family income level
<$60,000 Reference category
$60,000+ 0.112 0.003
Self-reported depression
No Reference category
Yes -0.150 <0.001
Any other comorbidities*
No Reference category
Yes -0.029 0.453
Migraine with aura
No Reference category
Yes -0.073 0.073
Severe migraine pain†
No Reference category
Yes 0.013 0.768
Migraine duration
<24 hours Reference category
24+ hours -0.040 0.360
Migraine disruptiveness‡
No Reference category
Yes -0.092 0.020
Migraines per month§ -0.039 <0.001
*Any comorbidity other than depression.
†Pain of 9 or 10 on a pain scale 1 to 10 (1 =mild, 10 = severe).
‡Migraines rated as “moderately” or “very” disruptive on 5-point Likert scale.
§Speciﬁed as a continuous variable.
Note: The model also include site and interaction of age and migraine frequency.
Model R2 = 0.365, F-value = 4.27, P < 0.001.
HUI3, Health Utilities Index Mark 3.
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Conclusions
To our knowledge, this is the ﬁrst study of migraine
patients to assess health preferences using the HUI3.
Using a combination of HUI3 utility scores andMIDAS
evaluations, we found that migraineurs’ level of disabil-
ity is inversely related to headache frequency. After
controlling for study site, sociodemographics, and clini-
cal characteristics, migraine frequency was the only
migraine characteristic that was statistically and nega-
tively associated with HUI3 global utility scores. Self-
reported migraine pain severity, presence of aura, and
migraine duration were not signiﬁcant predictors of
HUI3 scores. The ﬁnding that self-reported pain sever-
ity was not associated with HUI3 score may be due to
the lack of variation in reported pain; one-half of
patients rated the pain of a typical migraine as 8 or
above on a scale of 1 (no pain) to 10 (severe pain). We
tested various alternative models (e.g., multiple interac-
tion terms, including/excluding variables) and variable
speciﬁcations (e.g., pain speciﬁed as greater than or less
than 5, 7, and 8, duration speciﬁed as greater than or
less than 12 hours) and did not observe a difference in
the overall ﬁndings.
Most disability was found in the emotion, cogni-
tion, and pain components of HUI3, indicating the
speciﬁc pathways by which migraine headaches impact
overall health utility. Disability in the pain attribute
was expected and helps validate the HUI3 measure in
migraine. Disability in the emotion and cognition com-
ponents may be related to the presence of other neu-
rological conditions (e.g., depression) [7–9] and the
high level of disruptiveness to family and friends
attributed to migraines and migraine frequency.
Previous health status studies have reported that
migraine patients have a lower quality of life, based on
various measures, than that of the general population
[9,15,16,18,22,28]. This was also seen in our study:
subjects had a mean HUI3 global score of 0.62, com-
pared with a mean HUI3 score of 0.86 for a US com-
munity sample aged 18 to 44 years of age and 0.78 for
those aged 45 to 64 years [29]. Comparing our results
with HUI3 studies in other clinical areas can help put
our ﬁndings for migraineurs in broader perspective.
Persons in our study had similar HUI3 global utility
scores to a cross-sectional sample of patients with Type
2 diabetes (0.64) [30] and those with intermittent clau-
dication eligible for revascularization (0.66) [31]. The
mean HUI3 scores for subjects in our study were lower
than those of patients visiting a rheumatology clinic
(0.68) [32], but higher than that of patients with
difﬁcult-to-control epilepsy (0.56) [33] and mild or
moderate Alzheimer’s disease (0.39 and 0.19, respec-
tively) [34]. Although each of these studies reported
HUI3 scores, the study methodologies are not neces-
sarily consistent, and direct comparisons should be
made with caution.
Treatment strategies for migraine have primarily
targeted management of acute episodes. Preventive
therapy is recommended for those with frequent or
disabling attacks [35,36], and there is some evidence
Table 5 Unadjusted and adjusted mean HUI3 global scores by
patient-reported number of migraines per month
Number of patient-reported
migraines per month
Mean (SD) HUI3
global utility score
Unadjusted Adjusted*
2 0.68 (0.25) 0.67 (0.44)
>2 to 4 0.63 (0.26) 0.57 (0.35)
>4 to 6 0.60 (0.21) 0.52 (0.28)
6+ 0.55 (0.22) 0.41 (0.59)
*Based on the analysis of covariance results,adjusted for study site,demographics (age,
sex,income),and clinical characteristics (comorbidities,migraine pain severity,presence
of aura,migraine duration,and disruptiveness of migraine to family and friends),and the
interaction of migraine frequency and age.Trend is signiﬁcant (P = 0.043).
HUI3, Health Utilities Index Mark 3.
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that prevention is cost-effective [37–39]. Medications
used for migraine prevention include beta-blockers
(e.g., propranolol), tricyclic antidepressants (e.g., ami-
triptyline), serotonin antagonists, and neuromodula-
tors (e.g., topiramate and divalproex sodium) [40–43].
Public and private health-care purchasers in the
United States and abroad are increasingly demanding
comparative cost-effectiveness evaluations of new
therapies such as those for migraine prevention, but
those analyses are often limited because relevant
health utility data are not available. The health utility
data presented here can be used to estimate changes in
quality-adjusted life years from preventive migraine
treatment and may prove useful in assessing the
comparative cost-effectiveness of various preventive
migraine therapies [44].
The strengths of our study include a relatively large
sample size for a health utility study, inclusion of a
disease-speciﬁc health status measure (MIDAS), the
geographic diversity and variation in the method of
health-care delivery of the study sites, and the range of
assessments included in the questionnaire. As for limi-
tations, this was a cross-sectional survey of treatment-
seeking patients, and as such, our sample is not
representative of the overall migraine population.
The American Migraine Prevalence and Prevention
study—an epidemiological survey of US households
to identify of the prevalence of migraine—found
that, based on the MIDAS questionnaire, 64% of
migraineurs had little to no disability (MIDAS Grade I)
and 11% had severe disability (MIDAS Grade IV) [4].
In comparison, 41% of our cohort reported severe
disability and only 14% reported little or no disability
based on the MIDAS questionnaire. As such, our ﬁnd-
ings may not apply to persons who are able to manage
their condition through self-care or have less frequent
migraines; most migraine patients experience far fewer
migraines permonth than our study cohort [4]. Another
limitation of our study is thatwewere not able to review
subjects’ medical charts, which might have helped
control for other potential confounders in relating
migraine frequency to health utilities.We also could not
compare our cohort to the underlying populations at
the three study centers. In addition, it should be noted
that there is some debate over the validity of multi-
plicative multi-attribute utility functions such as those
used in the development of the HUI3 [45]. Finally, we
did not assess the relationship between acute and pre-
ventive migraine treatments, as the data collected for
this utility study were inappropriate to support such an
evaluation of the impact of those treatments.
In summary, our study of care-seeking migraineurs
suggests that these patients suffer from fairly frequent
migraines, and their self-reported health status is
inversely related to headache frequency. Moreover,
these individuals, on average, had health utility scores
in linewith other patients who have debilitating chronic
illnesses. These ﬁndings suggest that reducing migraine
frequency may ease the burden of migraine headache
and improve the quality of life for migraineurs.
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